Search PubMed⌕ Search

Biomedical subjects

B Morrow

Publications and source records attributed to B Morrow.

58 records · Page 4Linked to original sources
PubMed1980

Use of polyestradiol phosphate and anti-17 beta estradiol antibodies for the localization of estrogen receptors in target tissues: a critique.

Polyestradiol phosphate (PEP) has been used for localization of estrogen receptors in human carcinoma. The nature of PEP binding to the receptor molecule and the ability of antiestradiol antibodies to react with estrogen receptor complexes were investigated, using an animal model system. Castrated adult female rats were injected with PEP, estradiol 17 beta-diethylstilbestrol or saline. An estrogen target organ (uterus) and a non-target organ (diaphragm) were removed from each animal. In each organ, unoccupied cytosolic estrogen receptors were quantified by DCC assay. The tissue sections were processed to ascertain the PEP binding and the ability of antiestradiol antibodies to detect hormone-occupied sites. Comparison of the results obtained by DCC assay and immunohistochemical technique revealed that antiestradiol antibodies do not react with estradiol receptor complexes formed in vitro or in vivo; that PEP cannot compete with estradiol for the receptor sites in vitro; and that PEP binds to proteins other than those measured by DCC as receptor molecules having high affinity for estradiol.

Animals↗
PubMedDate not supplied

Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease.

Standard treatment for venous thromboembolism is parenteral heparin followed by warfarin. In this study we assess whether a standardized method of ordering warfarin reduces the duration of hospitalization. Consecutive patients were randomized to receive warfarin managed by attending physicians or by a nomogram. Patients were stratified according to primary or secondary venous thromboembolism. Prothrombin times were measured daily and heparin was given for a minimum of 5 days and stopped when the International Normalized Ratio was >1.9. Patients were followed for 3 months. There were 111 patients, 80 with primary and 31 with secondary venous thromboembolism. Overall there were no differences between the two warfarin groups with respect to length of admission. Given the prolonged duration of admission in many patients with secondary venous thromboembolism, a subset analysis was conducted on the 80 patients with primary venous thromboembolism. Patients in the standard group stayed significantly longer than patients in the nomogram group (6.0 vs. 5.6 days, p = 0.02). The warfarin nomogram as tested is safe and leads to a significantly shorter length of stay for patients with primary venous thromboembolism as compared to standard practice.

Administration, Oral↗